{"id":"human-interferon-1b-inhalation-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Local respiratory irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon α1b is a recombinant human interferon that engages type I interferon receptors (IFNAR1/IFNAR2) on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes, enhance natural killer cell activity, and promote Th1-mediated immune responses. When delivered via inhalation, it provides local immune activation in the respiratory tract, making it particularly suited for viral respiratory infections.","oneSentence":"Human interferon α1b activates innate immune responses by binding to interferon-alpha receptors on immune and epithelial cells, enhancing antiviral and immunomodulatory activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:54.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Viral respiratory infections (Phase 3 development)"},{"name":"COVID-19 (potential indication under investigation)"}]},"trialDetails":[{"nctId":"NCT06363370","phase":"PHASE3","title":"Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections","status":"RECRUITING","sponsor":"Kexing Biopharm Co., Ltd.","startDate":"2024-03-27","conditions":"Respiratory Syncytial Virus Infections","enrollment":322}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Human interferon α1b Inhalation Solution","genericName":"Human interferon α1b Inhalation Solution","companyName":"Kexing Biopharm Co., Ltd.","companyId":"kexing-biopharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Human interferon α1b activates innate immune responses by binding to interferon-alpha receptors on immune and epithelial cells, enhancing antiviral and immunomodulatory activity. Used for Viral respiratory infections (Phase 3 development), COVID-19 (potential indication under investigation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}